Published in Am J Cardiol on September 15, 1999
Ventilatory expired gas at constant-rate low-intensity exercise predicts adverse events and is related to neurohormonal markers in patients with heart failure. J Card Fail (2009) 0.92
Functional electrical stimulation of lower limbs in patients with chronic heart failure. Heart Fail Rev (2010) 0.86
Oxygen uptake kinetics in chronic heart failure: clinical and physiological aspects. Neth Heart J (2009) 0.84
Reproducibility of onset and recovery oxygen uptake kinetics in moderately impaired patients with chronic heart failure. Eur J Appl Physiol (2007) 0.84
Submaximal oxygen uptake kinetics, functional mobility, and physical activity in older adults with heart failure and reduced ejection fraction. J Geriatr Cardiol (2016) 0.75
V̇O2 Kinetics Associated with Moderate Intensity Exercise in Heart Failure: Impact of Intrathecal Fentanyl Inhibition of Group III/IV Locomotor Muscle Afferents. Am J Physiol Heart Circ Physiol (2017) 0.75
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J (2003) 3.78
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J (2003) 2.78
Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J (2004) 2.73
The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J (2002) 2.68
Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet (2002) 2.61
One-year mortality among unselected outpatients with heart failure. Eur Heart J (2002) 2.30
Serum level monitoring of antibacterial drugs. A review. Clin Pharmacokinet (1985) 2.01
Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation (1990) 1.98
Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens (2003) 1.93
Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. Circulation (1990) 1.86
Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J (1999) 1.83
Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol (2000) 1.82
Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. N Engl J Med (1987) 1.80
Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) J Am Coll Cardiol (1990) 1.76
Management of patients with heart failure in clinical practice: differences between men and women. Heart (2007) 1.73
Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther (1983) 1.73
Decreased Beta-adrenoreceptor responsiveness as related to age, blood pressure, and plasma catecholamines in patients with essential hypertension. Hypertension (1980) 1.69
Langerhans'-cell histiocytosis in adults. Med Pediatr Oncol (1997) 1.62
Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation. Clin Pharmacol Ther (1982) 1.51
Effects of the Tibetan herbal preparation PADMA 28 on blood lipids and lipid oxidisability in subjects with mild hypercholesterolaemia. Vasa (2005) 1.49
ICD implantation with and without combined myocardial revascularisation--incidence of ICD therapy and late survival. Thorac Cardiovasc Surg (2002) 1.42
Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. Circulation (1993) 1.42
Re: 'Ventricular arrhythmias induced by endothelin-1 or by acute ischemia: a comparative analysis using three dimensional mapping' (Cardiovasc Res 2000;45:310-320). Cardiovasc Res (2000) 1.41
Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial. Eur Heart J (1999) 1.41
Is blood pressure response to the Valsalva maneuver related to neurohormones, exercise capacity, and clinical findings in heart failure? Chest (1999) 1.40
Images in cardiovascular medicine. Idiopathic hypereosinophilic vasculitis. Circulation (1995) 1.39
Effect of experimental cerebral infarction in rat brain on catecholamines and behaviour. Nature (1975) 1.38
Prognosis of medically treated patients referred for cardiac transplantation. Int J Cardiol (1998) 1.38
Long term follow up of prosthetic valve endocarditis: what characteristics identify patients who were treated successfully with antibiotics alone? Heart (1999) 1.26
Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res (1997) 1.25
Prenatal adverse effects of nicotine on the developing brain. Prog Brain Res (1988) 1.23
Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation (1998) 1.22
Force and torque effects of a 1.5-Tesla MRI scanner on cardiac pacemakers and ICDs. Pacing Clin Electrophysiol (2001) 1.19
Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered aminophylline. Am Rev Respir Dis (1982) 1.18
Calcium antagonists in hypertension. J Hypertens Suppl (1987) 1.18
Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol (1995) 1.16
Multicompartment pharmacokinetics of netilmicin. Eur J Clin Pharmacol (1979) 1.16
Age-related decrease in cardiac and peripheral vascular responsiveness to isoprenaline: studies in normal subjects. Clin Sci (Lond) (1981) 1.14
Sunscreens: are they beneficial for health? An overview of endocrine disrupting properties of UV-filters. Int J Androl (2012) 1.12
Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol (1998) 1.12
Drug-induced pulmonary hypertension? Br Med J (1971) 1.12
The place of the calcium antagonist verapamil in antihypertensive therapy. J Cardiovasc Pharmacol (1982) 1.11
Lethal autoimmune myocarditis in interferon-gamma receptor-deficient mice: enhanced disease severity by impaired inducible nitric oxide synthase induction. Circulation (2001) 1.10
High thresholds may alter end-of-life behavior in a dual chamber pacemaker. Pacing Clin Electrophysiol (1997) 1.09
The vasodilator potency of atrial natriuretic peptide in man. Circulation (1987) 1.07
Influence of chronic dosing on theophylline clearance. Br J Clin Pharmacol (1985) 1.07
Hyperparathyroidism in congestive heart failure. Am J Med (1998) 1.07
Population pharmacokinetics of tobramycin. Br J Clin Pharmacol (1989) 1.07
Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine. J Am Coll Cardiol (1986) 1.05
Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol (1996) 1.03
Effect of beta adrenoceptor antagonists on baroreceptor reflex sensitivity in hypertension. Clin Pharmacol Ther (1977) 1.01
Reliability of antiarrhythmic drug plasma concentration monitoring. Clin Pharmacokinet (1983) 1.00
Mixtures of endocrine disrupting contaminants modelled on human high end exposures: an exploratory study in rats. Int J Androl (2012) 1.00
Alpha 2 adrenoceptor-mediated vasoconstriction of arteries. Clin Pharmacol Ther (1983) 0.99
Heart valve replacement with St. Jude Medical valve prosthesis. Long-term experience in 743 patients in Switzerland. Circulation (1988) 0.99
Predicting individual phenytoin dosage. J Pharmacokinet Biopharm (1981) 0.98
Enhanced vasodilatation in essential hypertension by calcium channel blockade with verapamil. Hypertension (1982) 0.97
Differently labelled glucosamine-precursor pools for the biosynthesis of hyaluronate and heparan sulfate. Eur J Biochem (1973) 0.96
Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine. Eur J Clin Pharmacol (1986) 0.96
Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol (1992) 0.95
Biochemical and anatomical effects of antibodies against nerve growth factor on developing rat sensory ganglia. Proc Natl Acad Sci U S A (1984) 0.95
Plasma noradrenaline concentration and alpha-adrenoceptor-mediated vasoconstriction in normotensive and hypertensive man. Clin Sci (Lond) (1981) 0.95
Plasma concentration monitoring of aminoglycosides. J Antimicrob Chemother (1981) 0.95
Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol (1995) 0.95
Changes in the apparent half life of gentamicin and tobramycin without detectable changes in creatinine clearance. Br J Clin Pharmacol (1979) 0.94
Studies of the bioavailability of nitroglycerin from a transdermal therapeutic system (Nitroderm TTS). Eur J Clin Pharmacol (1984) 0.94
Temperature dependency of apparent cyclosporin A concentrations in plasma. Clin Chem (1983) 0.94
Stimulation of nigrostriatal dopamine neurones by nicotine. Neuropharmacology (1982) 0.94
Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med (1984) 0.94
Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation (1994) 0.93
A comparison of cardiovascular effects of dobutamine and isoprenaline after open heart surgery. Br Heart J (1976) 0.93
Factors influencing the hypotensive effects of calcium antagonists. Hypertension (1983) 0.92
Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol (1992) 0.92
Population pharmacokinetics of quinidine. Br J Clin Pharmacol (1991) 0.92
A fluorometric micromethod for the simultaneous determination of serotonin, noradrenaline and dopamine in milligram amounts of brain tissue. Biochem Pharmacol (1974) 0.91
MR imaging in patients with cardiac pacemakers. Radiology (2001) 0.91
[Aortic valve insufficiency in Crohn disease]. Schweiz Med Wochenschr (1997) 0.91
Spontaneous multivessel coronary artery dissection in a pregnant woman treated successfully with stent implantation. Am J Med (1999) 0.91
Arterial vasodilator, systemic and coronary hemodynamic effects of nisoldipine in congestive heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol (1987) 0.91
[Congenital left ventricular aneurysms and diverticula: clinical findings, diagnosis and course]. Schweiz Med Wochenschr (1999) 0.91
Antihypertensive efficacy of ketanserin alone or in combination with a beta-blocker or a diuretic: the Swiss Ketanserin Study. J Cardiovasc Pharmacol (1987) 0.91
Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J Hepatol (2001) 0.90
Assessment of stenoses in coronary angioplasty. Inter- and intraobserver variability. Int J Cardiol (1983) 0.90
Interaction between amiodarone and lidocaine. J Cardiovasc Pharmacol (1996) 0.90
Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J Am Coll Cardiol (2000) 0.90
Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. J Cardiovasc Pharmacol (1985) 0.89
Cardiovascular effects of a new inotropic drug in dog and normal man. Clin Pharmacol Ther (1976) 0.89
Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J Clin Endocrinol Metab (1998) 0.89
Adenosine-induced non-sustained polymorphic ventricular tachycardia. Eur Heart J (1994) 0.89